BR112018071678A2 - compostos terapêuticos úteis para o tratamento profilático ou terapêutico de uma infecção por vírus hiv - Google Patents

compostos terapêuticos úteis para o tratamento profilático ou terapêutico de uma infecção por vírus hiv

Info

Publication number
BR112018071678A2
BR112018071678A2 BR112018071678-2A BR112018071678A BR112018071678A2 BR 112018071678 A2 BR112018071678 A2 BR 112018071678A2 BR 112018071678 A BR112018071678 A BR 112018071678A BR 112018071678 A2 BR112018071678 A2 BR 112018071678A2
Authority
BR
Brazil
Prior art keywords
therapeutic
prophylactic
hiv virus
virus infection
compounds useful
Prior art date
Application number
BR112018071678-2A
Other languages
English (en)
Other versions
BR112018071678B1 (pt
Inventor
Graupe Michael
J. Henry Steven
O. Link John
William Rowe Charles
D. Saito Roland
D. Schroeder Scott
Stefanidis Dimitrios
C. Tse Winston
R. Zhang Jennifer
Original Assignee
Gilead Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59714166&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112018071678(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences, Inc. filed Critical Gilead Sciences, Inc.
Priority to BR122020001791-0A priority Critical patent/BR122020001791B1/pt
Publication of BR112018071678A2 publication Critical patent/BR112018071678A2/pt
Publication of BR112018071678B1 publication Critical patent/BR112018071678B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/02—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms
    • C07C317/08—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms of an acyclic unsaturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

a presente invenção refere-se a um composto de fórmula (ia), (ib), (iia) e (iib): (ia), (ib), (iia), (iib) que são úteis no tratamento de uma infecção viral por retroviridae incluindo uma infecção causada pelo vírus hiv.
BR112018071678-2A 2016-08-19 2017-08-17 compostos terapêuticos úteis para o tratamento profilático ou terapêutico de uma infecção por vírus hiv e suas composições farmacêuticas BR112018071678B1 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122020001791-0A BR122020001791B1 (pt) 2016-08-19 2017-08-17 Usos de compostos terapêuticos no tratamento profilático ou terapêutico de uma infecção por vírus hiv

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662377312P 2016-08-19 2016-08-19
US62/377,312 2016-08-19
US201762457555P 2017-02-10 2017-02-10
US62/457,555 2017-02-10
PCT/US2017/047416 WO2018035359A1 (en) 2016-08-19 2017-08-17 Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection

Publications (2)

Publication Number Publication Date
BR112018071678A2 true BR112018071678A2 (pt) 2019-02-19
BR112018071678B1 BR112018071678B1 (pt) 2021-01-26

Family

ID=59714166

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112018071678-2A BR112018071678B1 (pt) 2016-08-19 2017-08-17 compostos terapêuticos úteis para o tratamento profilático ou terapêutico de uma infecção por vírus hiv e suas composições farmacêuticas
BR122020001791-0A BR122020001791B1 (pt) 2016-08-19 2017-08-17 Usos de compostos terapêuticos no tratamento profilático ou terapêutico de uma infecção por vírus hiv

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR122020001791-0A BR122020001791B1 (pt) 2016-08-19 2017-08-17 Usos de compostos terapêuticos no tratamento profilático ou terapêutico de uma infecção por vírus hiv

Country Status (40)

Country Link
US (3) US10071985B2 (pt)
EP (3) EP3347352B1 (pt)
JP (4) JP6716785B2 (pt)
KR (3) KR20200131351A (pt)
CN (2) CN109890808B (pt)
AU (4) AU2017312102B2 (pt)
BR (2) BR112018071678B1 (pt)
CA (1) CA3021227C (pt)
CL (1) CL2019000415A1 (pt)
CO (1) CO2019001379A2 (pt)
CR (1) CR20190084A (pt)
CY (1) CY1122296T1 (pt)
DK (2) DK3347352T3 (pt)
DO (1) DOP2019000033A (pt)
EC (1) ECSP19011209A (pt)
ES (2) ES2746374T3 (pt)
FI (1) FI3597646T3 (pt)
FR (1) FR22C1063I2 (pt)
HK (1) HK1256904B (pt)
HR (1) HRP20231018T1 (pt)
HU (3) HUE063811T2 (pt)
IL (1) IL264644B (pt)
JO (1) JOP20180123A1 (pt)
LT (3) LT3597646T (pt)
MA (2) MA42795B1 (pt)
MX (1) MX369307B (pt)
MY (1) MY191466A (pt)
NL (1) NL301212I2 (pt)
NZ (1) NZ750706A (pt)
PE (2) PE20190910A1 (pt)
PH (1) PH12019500335A1 (pt)
PL (2) PL3597646T3 (pt)
PT (2) PT3597646T (pt)
SA (1) SA519401123B1 (pt)
SG (2) SG10201912535VA (pt)
SI (2) SI3347352T1 (pt)
TW (4) TW202342449A (pt)
UY (1) UY37367A (pt)
WO (1) WO2018035359A1 (pt)
ZA (1) ZA201901430B (pt)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6205354B2 (ja) 2011-07-06 2017-09-27 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖの処置のための化合物
US10202353B2 (en) 2014-02-28 2019-02-12 Gilead Sciences, Inc. Therapeutic compounds
PE20190910A1 (es) 2016-08-19 2019-06-26 Gilead Sciences Inc Compuestos terapeuticos utiles para el tratamiento profilactico o terapeutico de una infeccion por el virus del vih
AR112412A1 (es) * 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
AR112413A1 (es) * 2017-08-17 2019-10-23 Gilead Sciences Inc Formas sólidas de un inhibidor de la cápside del vih
WO2019161017A1 (en) 2018-02-15 2019-08-22 Gilead Sciences, Inc. Pyridine derivatives and their use for treating hiv infection
CA3175557A1 (en) * 2018-02-16 2019-08-22 Gilead Sciences, Inc. Methods and intermediates for preparing a therapeutic compound useful in the treatment of retroviridae viral infection
WO2019246545A1 (en) * 2018-06-21 2019-12-26 Drexel University Small-molecule hiv-1 capsid protein inhibitors and methods using same
WO2020018459A1 (en) * 2018-07-16 2020-01-23 Gilead Sciences, Inc. Capsid inhibitors for the treatment of hiv
EP3833436A1 (en) * 2018-08-09 2021-06-16 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
WO2020053811A1 (en) 2018-09-14 2020-03-19 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
JP7433303B2 (ja) 2018-09-20 2024-02-19 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド ヒト免疫不全ウイルス複製の阻害剤
WO2020084492A1 (en) 2018-10-24 2020-04-30 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
US20210395262A1 (en) 2018-10-24 2021-12-23 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
PT3870575T (pt) 2018-10-25 2023-05-12 Viiv Healthcare Uk No 5 Ltd Inibidores da replicação do vírus da imunodeficiência humana
ES2969030T3 (es) 2018-10-29 2024-05-16 Viiv Healthcare Uk No 5 Ltd Derivados de quinazolinil-indazol y su uso como inhibidores de replicación de virus de inmunodeficiencia humana
US20210379071A1 (en) 2018-11-05 2021-12-09 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
WO2020095177A1 (en) 2018-11-05 2020-05-14 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
UA128041C2 (uk) 2019-01-25 2024-03-20 Браун Юніверсіті Спосіб лікування пов'язаного з віком запалення у пацієнта
UY38559A (es) 2019-02-01 2020-07-31 Viiv Healthcare Uk No 5 Ltd Inhibidores de la replicación del virus de la inmunodeficiencia humana
JP2022531251A (ja) 2019-04-30 2022-07-06 ビーブ、ヘルスケア、ユーケー、（ナンバー５）、リミテッド ヒト免疫不全ウイルス複製阻害剤
RU2717101C1 (ru) 2019-06-03 2020-03-18 Андрей Александрович Иващенко Анелированные 9-гидрокси-1,8-диоксо-1,3,4,8-тетрагидро-2Н-пиридо[1,2-a]пиразин-7-карбоксамиды - ингибиторы интегразы ВИЧ, способы их получения и применения
WO2020254985A1 (en) * 2019-06-19 2020-12-24 VIIV Healthcare UK (No.5) Limited Pyrido[2,3-d]pyrimidine derivatives as inhibitors of human immunodeficiency virus replication
JP2022551256A (ja) 2019-10-01 2022-12-08 ビーブ、ヘルスケア、ユーケー、（ナンバー５）、リミテッド ヒト免疫不全ウイルスの複製阻害剤
US20220389007A1 (en) 2019-10-01 2022-12-08 Viiv Healthcare Uk (No. 5) Limited Inhibitors of human immunodeficiency virus replication
TW202128648A (zh) 2019-10-04 2021-08-01 英商Ｖｉｉｖ醫療保健英國(Ｎｏ 5)有限公司 人類免疫不全病毒複製之抑制劑
US20220370451A1 (en) 2019-10-08 2022-11-24 VIIV HEALTHCARE UK ( No. 5) LIMITED Inhibitors of human immunodeficiency virus replication
EP4065116A1 (en) * 2019-11-26 2022-10-05 Gilead Sciences, Inc. Capsid inhibitors for the prevention of hiv
WO2021107066A1 (ja) 2019-11-28 2021-06-03 塩野義製薬株式会社 インテグラーゼ阻害剤及び抗ｈｉｖ薬を組み合わせることを特徴とするｈｉｖ感染症の予防及び治療用医薬
MX2022006489A (es) 2019-11-29 2022-07-04 Jiangsu Hengrui Medicine Co Derivado de anillo de piridina fusionado, metodo de preparacion y usos farmaceuticos del mismo.
CN113304166B (zh) * 2020-02-27 2022-10-14 河南真实生物科技有限公司 核苷类化合物在制备治疗冠状病毒感染性疾病的药物中的用途
JP2023517312A (ja) 2020-03-06 2023-04-25 ビーブ、ヘルスケア、ユーケー、（ナンバー５）、リミテッド ヒト免疫不全ウイルスの複製阻害剤
KR20220151655A (ko) 2020-03-06 2022-11-15 비브 헬스케어 유케이 (넘버5) 리미티드 인간 면역결핍 바이러스 복제의 억제제
AU2021237718B2 (en) 2020-03-20 2023-09-21 Gilead Sciences, Inc. Prodrugs of 4'-C-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
BR112022020933A2 (pt) 2020-04-15 2022-12-06 Viiv Healthcare Uk No 5 Ltd Inibidores de replicação do vírus da imunodeficiência humana
EP4153181A1 (en) 2020-05-21 2023-03-29 Gilead Sciences, Inc. Pharmaceutical compositions comprising bictegravir
WO2021262990A1 (en) * 2020-06-25 2021-12-30 Gilead Sciences, Inc. Capsid inhibitors for the treatment of hiv
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
CN116437958A (zh) 2020-11-11 2023-07-14 吉利德科学公司 鉴定对采用gp120 CD4结合位点导向的抗体的疗法敏感的HIV患者的方法
TW202237146A (zh) * 2021-01-25 2022-10-01 美商布里生物科學股份有限公司 使用腺苷衍生物及衣殼抑制劑之hiv組合療法
TW202313584A (zh) * 2021-05-28 2023-04-01 大陸商江蘇恒瑞醫藥股份有限公司 稠合吡啶環衍生物的可藥用鹽、晶型及其製備方法
KR20230019059A (ko) 2021-07-30 2023-02-07 (주) 에빅스젠 연전초 추출물을 유효성분으로 포함하는, 바이러스성 질환 완화 및 개선용 조성물
KR20230018690A (ko) 2021-07-30 2023-02-07 (주) 에빅스젠 둥근이질풀 추출물을 유효성분으로 포함하는, 바이러스성 질환 치료 및 개선용 조성물
CA3237155A1 (en) 2021-12-03 2023-06-08 Zhimin Du Therapeutic compounds for hiv virus infection
WO2023102523A1 (en) 2021-12-03 2023-06-08 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
US11787825B2 (en) 2021-12-03 2023-10-17 Gilead Sciences, Inc. Therapeutic compounds for HIV virus infection
TW202400172A (zh) 2022-04-06 2024-01-01 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
TW202402280A (zh) * 2022-07-01 2024-01-16 美商基利科學股份有限公司 可用於ｈｉｖ病毒感染之疾病預防性或治療性治療的治療性化合物
WO2024044477A1 (en) 2022-08-26 2024-02-29 Gilead Sciences, Inc. Dosing and scheduling regimen for broadly neutralizing antibodies
WO2024076915A1 (en) 2022-10-04 2024-04-11 Gilead Sciences, Inc. 4'-thionucleoside analogues and their pharmaceutical use
KR20240061218A (ko) 2022-10-31 2024-05-08 주식회사 이보드 복합 단열재 및 제조방법

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816570A (en) 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
ES2083580T3 (es) 1990-06-13 1996-04-16 Arnold Glazier Profarmacos de fosforo.
DK0481214T3 (da) 1990-09-14 1999-02-22 Acad Of Science Czech Republic Prolægemidler af phosphonater
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US5935946A (en) 1997-07-25 1999-08-10 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
ES2536972T5 (es) 2000-07-21 2022-04-06 Gilead Sciences Inc Profármacos de análogos de nucleótidos de fosfonato y métodos para seleccionar y preparar los mismos
US7196201B2 (en) 2001-06-27 2007-03-27 Smithkline Beecham Corporation Pyrrolidines as dipeptidyl peptidase inhibitors
ATE370943T1 (de) 2001-06-27 2007-09-15 Smithkline Beecham Corp Fluoropyrrolidine als dipeptidyl-peptidase inhibitoren
WO2003035076A1 (en) 2001-10-26 2003-05-01 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Dihydroxypyrimidine carboxamide inhibitors of hiv integrase
US7642277B2 (en) 2002-12-04 2010-01-05 Boehringer Ingelheim International Gmbh Non-nucleoside reverse transcriptase inhibitors
WO2004071448A2 (en) 2003-02-12 2004-08-26 Transtech Pharma Inc. Substituted azole derivatives as inhibitors of protein tyrosine phosphatases
SG182849A1 (en) 2003-04-25 2012-08-30 Gilead Sciences Inc Antiviral phosphonate analogs
DE602005023224D1 (de) 2004-02-27 2010-10-07 Schering Corp Neuartige Verbindungen als Hemmer von Hepatitis C-Virus NS3-Serinprotease
US7453002B2 (en) 2004-06-15 2008-11-18 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors
US7429604B2 (en) 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
EP2258376B1 (en) 2004-07-27 2019-02-27 Gilead Sciences, Inc. Phosphonate analogs of HIV inhibitor compounds
US8067587B2 (en) 2005-07-28 2011-11-29 Lenroc Company Process for the production of monoalkali metal cyanurates
US20070032469A1 (en) 2005-08-05 2007-02-08 Astrazeneca Ab Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators
WO2007070826A1 (en) 2005-12-14 2007-06-21 Bristol-Myers Squibb Company Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors
AU2007238755B2 (en) 2006-04-12 2012-07-12 Merck Sharp & Dohme Llc Pyridyl amide T-type calcium channel antagonists
US7647464B2 (en) 2006-04-28 2010-01-12 At&T Intellectual Property, I,L.P. Methods, systems, and products for recording media to a restoration server
WO2008013622A2 (en) 2006-07-27 2008-01-31 E. I. Du Pont De Nemours And Company Fungicidal azocyclic amides
US8124811B2 (en) 2007-03-20 2012-02-28 Allylix, Inc. Fragrance and methods for production of 5-epi-β-vetivone, 2-isopropyl-6,10-dimethyl-spiro[4.5]deca-2,6-dien-8-one, and 2-isopropyl-6,10-dimethyl-spiro[4.5]deca-1,6-dien-8-one
CN101702908A (zh) 2007-03-23 2010-05-05 麻萨诸塞州大学 Hiv-1蛋白酶抑制剂
CN101801925A (zh) 2007-06-29 2010-08-11 吉里德科学公司 抗病毒组合物
AU2008274185B2 (en) 2007-07-12 2014-07-03 Janssen Sciences Ireland Uc Crystalline form of (E) 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2 pyrimidinyl]amino]benzonitrile
CA2699891C (en) 2007-07-19 2013-10-22 Nigel Liverton Macrocyclic compounds as antiviral agents
US20100249176A1 (en) 2007-10-24 2010-09-30 Barrow James C Heterocycle amide t-type calcium channel antagonists
KR20100072266A (ko) 2007-10-24 2010-06-30 머크 샤프 앤드 돔 코포레이션 헤테로사이클 페닐 아미드 ｔ-형 칼슘 채널 길항제
EP2220046B1 (en) 2007-11-16 2014-06-18 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
CN102026996B (zh) 2008-03-13 2015-01-07 百时美施贵宝公司 作为凝血因子xia抑制剂的哒嗪衍生物
KR101687841B1 (ko) 2008-12-09 2016-12-19 길리애드 사이언시즈, 인코포레이티드 톨-유사 수용체의 조절제
EP2401286A4 (en) 2009-02-25 2012-09-26 Bigtec Private Ltd PROBES AND PRIMERS FOR DETECTION OF CHIKUNGUNYA
US8338441B2 (en) 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
US20110274648A1 (en) 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
WO2011094890A1 (en) 2010-02-02 2011-08-11 Argusina Inc. Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
WO2011139637A1 (en) 2010-05-03 2011-11-10 Philadelphia Health & Education Corporation Small-molecule modulators of hiv-1 capsid stability and methods thereof
WO2011143772A1 (en) 2010-05-21 2011-11-24 Boehringer Ingelheim International Gmbh Inhibitors of hiv replication
AP2013006706A0 (en) 2010-07-02 2013-02-28 Gilead Sciences Inc Napht-2-ylacetic acid derivatives to treat AIDS
CN103209963A (zh) 2010-07-02 2013-07-17 吉里德科学公司 作为hiv抗病毒化合物的2-喹啉基-乙酸衍生物
CN102464654B (zh) 2010-11-12 2016-01-13 上海泓博智源医药技术有限公司 抗病毒化合物
SI2688403T1 (sl) 2011-03-23 2017-08-31 Trevena, Inc. Ligandi opioidnih receptorjev in metode uporabe in izdelave istega
ES2707997T3 (es) 2011-04-21 2019-04-08 Gilead Sciences Inc Compuestos de benzotiazol y su uso farmacéutico
JP6205354B2 (ja) 2011-07-06 2017-09-27 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖの処置のための化合物
CN102863512B (zh) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 抗病毒化合物
AR087546A1 (es) 2011-08-16 2014-04-03 Gilead Sciences Inc Hemifumarato de tenofovir alafenamida
WO2013091096A1 (en) 2011-12-20 2013-06-27 Boehringer Ingelheim International Gmbh Condensed triclyclic compounds as inhibitors of hiv replication
JP5911638B2 (ja) 2012-04-20 2016-04-27 ギリアード サイエンシーズ， インコーポレイテッド ベンゾチアゾール−６−イル酢酸誘導体およびｈｉｖ感染を処置するためのそれらの使用
GB201213087D0 (en) 2012-07-24 2012-09-05 Medical Res Council Inhibition of HIV-1 infection
US9447134B2 (en) 2012-08-17 2016-09-20 Brandeis University Compounds and methods for treating mammalian gastrointestinal microbial infections
MD4736C1 (ro) 2012-12-21 2021-07-31 Gilead Sciences, Inc. Compus policiclic de carbamoilpiridonă şi utilizarea farmaceutică a acestuia
AR094311A1 (es) 2012-12-27 2015-07-22 Japan Tobacco Inc Derivados de tetrahidroespiro-ciclopropil-pirido[1,2-a]pirazina inhibidores de la integrasa del hiv
TW201443037A (zh) * 2013-01-09 2014-11-16 Gilead Sciences Inc 治療用化合物
WO2014110298A1 (en) 2013-01-09 2014-07-17 Gilead Sciences, Inc. 5-membered heteroaryls and their use as antiviral agents
PT2943493T (pt) 2013-01-09 2017-10-23 Gilead Sciences Inc Compostos terapêuticos para o tratamento de infecções virais
EP2769722A1 (en) 2013-02-22 2014-08-27 Ruprecht-Karls-Universität Heidelberg Compounds for use in inhibiting HIV capsid assembly
TWI694071B (zh) * 2013-03-01 2020-05-21 美商基利科學股份有限公司 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物
US20140296266A1 (en) 2013-03-01 2014-10-02 Gilead Sciences, Inc. Therapeutic compounds
GB201312991D0 (en) 2013-07-19 2013-09-04 Isis Innovation Process
US10035760B2 (en) 2013-10-24 2018-07-31 Viiv Healthcare Uk (No. 5) Limited Inhibitors of human immunodeficiency virus replication
US10202353B2 (en) 2014-02-28 2019-02-12 Gilead Sciences, Inc. Therapeutic compounds
WO2015130966A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Antiviral agents
PT3186239T (pt) 2014-08-29 2019-01-10 Gilead Sciences Inc Agentes antirretrovirais
US9855230B2 (en) 2014-09-09 2018-01-02 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
EP3237414B1 (en) 2014-12-24 2019-05-08 Gilead Sciences, Inc. Fused pyrimidine compounds for the tratment of hiv
TWI770552B (zh) 2014-12-24 2022-07-11 美商基利科學股份有限公司 喹唑啉化合物
CA2983162A1 (en) 2015-04-23 2016-10-27 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
UY36648A (es) 2015-04-23 2016-11-30 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Inhibidores de la replicación del virus de inmunodeficiencia humana
JP6430060B2 (ja) * 2015-07-06 2018-11-28 ギリアード サイエンシーズ， インコーポレイテッド Ｃｏｔモジュレーターおよびその使用方法
US10171985B1 (en) 2015-07-22 2019-01-01 Ginko LLC Method and apparatus for data sharing
PE20190910A1 (es) 2016-08-19 2019-06-26 Gilead Sciences Inc Compuestos terapeuticos utiles para el tratamiento profilactico o terapeutico de una infeccion por el virus del vih
JOP20180009A1 (ar) 2017-02-06 2019-01-30 Gilead Sciences Inc مركبات مثبط فيروس hiv
TW201906834A (zh) 2017-05-02 2019-02-16 英商Viiv醫療保健英國(No.5)有限公司 人類免疫不全病毒複製之抑制劑
AR112412A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
AR112413A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas sólidas de un inhibidor de la cápside del vih
WO2019161017A1 (en) 2018-02-15 2019-08-22 Gilead Sciences, Inc. Pyridine derivatives and their use for treating hiv infection
CA3175557A1 (en) 2018-02-16 2019-08-22 Gilead Sciences, Inc. Methods and intermediates for preparing a therapeutic compound useful in the treatment of retroviridae viral infection
US10911396B2 (en) 2018-06-28 2021-02-02 Paypal, Inc. Mid-tier messaging system
WO2020018459A1 (en) 2018-07-16 2020-01-23 Gilead Sciences, Inc. Capsid inhibitors for the treatment of hiv
EP4065116A1 (en) 2019-11-26 2022-10-05 Gilead Sciences, Inc. Capsid inhibitors for the prevention of hiv
WO2021262990A1 (en) 2020-06-25 2021-12-30 Gilead Sciences, Inc. Capsid inhibitors for the treatment of hiv

Also Published As

Publication number Publication date
HUS2200053I1 (hu) 2023-01-28
TW201922711A (zh) 2019-06-16
PH12019500335A1 (en) 2019-11-11
BR112018071678B1 (pt) 2021-01-26
HRP20231018T1 (hr) 2023-12-08
PL3597646T3 (pl) 2023-12-11
TWI664966B (zh) 2019-07-11
EP3347352A1 (en) 2018-07-18
AU2020202331A1 (en) 2020-04-23
TWI715944B (zh) 2021-01-11
US20200262815A1 (en) 2020-08-20
MA42795B1 (fr) 2019-08-30
US11993583B2 (en) 2024-05-28
FI3597646T3 (fi) 2023-09-07
AU2020202331B2 (en) 2021-05-27
JP2019528280A (ja) 2019-10-10
AU2023271739A1 (en) 2023-12-14
US10071985B2 (en) 2018-09-11
NZ750706A (en) 2020-07-31
WO2018035359A1 (en) 2018-02-22
SG10201912535VA (en) 2020-02-27
LT3597646T (lt) 2023-09-25
ZA201901430B (en) 2021-09-29
SG11201808944QA (en) 2018-11-29
HUE063811T2 (hu) 2024-02-28
PT3347352T (pt) 2019-09-24
JP6716785B2 (ja) 2020-07-01
CY1122296T1 (el) 2021-01-27
AU2017312102B2 (en) 2020-03-05
US10654827B2 (en) 2020-05-19
ES2954514T3 (es) 2023-11-22
MY191466A (en) 2022-06-28
SI3347352T1 (sl) 2019-08-30
MA50673A (fr) 2020-08-05
AU2017312102A1 (en) 2019-03-07
LT3347352T (lt) 2019-08-12
KR20190039431A (ko) 2019-04-11
MA42795A (fr) 2019-07-03
CN109890808A (zh) 2019-06-14
DK3597646T3 (da) 2023-09-04
NL301212I1 (pt) 2023-01-12
TW202342449A (zh) 2023-11-01
DK3347352T3 (da) 2019-08-26
KR20230011471A (ko) 2023-01-20
SA519401123B1 (ar) 2022-11-09
HK1256904B (zh) 2020-07-17
MX369307B (es) 2019-11-05
MX2018012905A (es) 2019-01-30
CR20190084A (es) 2019-05-02
PT3597646T (pt) 2023-09-11
AU2020202331C1 (en) 2021-08-26
JOP20180123A1 (ar) 2019-01-30
PE20190910A1 (es) 2019-06-26
KR102180740B1 (ko) 2020-11-20
IL264644B (en) 2019-09-26
CA3021227A1 (en) 2018-02-22
EP4265299A3 (en) 2024-01-17
AU2021221855A1 (en) 2021-09-23
CO2019001379A2 (es) 2019-02-19
ECSP19011209A (es) 2019-02-28
HUE045137T2 (hu) 2019-12-30
CN111793061A (zh) 2020-10-20
JP2023011754A (ja) 2023-01-24
TW202138365A (zh) 2021-10-16
JP2021008516A (ja) 2021-01-28
BR122020001791B1 (pt) 2022-01-25
CN109890808B (zh) 2020-08-07
UY37367A (es) 2018-03-23
KR20200131351A (ko) 2020-11-23
PL3347352T3 (pl) 2019-12-31
EP4265299A2 (en) 2023-10-25
EP3597646B1 (en) 2023-06-21
FR22C1063I2 (fr) 2023-12-15
LTPA2023501I1 (pt) 2023-02-10
US20180370950A1 (en) 2018-12-27
PE20211427A1 (es) 2021-08-03
EP3347352B1 (en) 2019-07-03
DOP2019000033A (es) 2019-03-15
CA3021227C (en) 2020-11-03
ES2746374T3 (es) 2020-03-05
CL2019000415A1 (es) 2019-06-21
FR22C1063I1 (fr) 2023-02-03
NL301212I2 (nl) 2023-04-06
EP3597646A1 (en) 2020-01-22
TW201811327A (zh) 2018-04-01
SI3597646T1 (sl) 2023-10-30
JP2020111592A (ja) 2020-07-27
US20180051005A1 (en) 2018-02-22
AU2021221855B2 (en) 2023-08-31

Similar Documents

Publication Publication Date Title
BR112018071678A2 (pt) compostos terapêuticos úteis para o tratamento profilático ou terapêutico de uma infecção por vírus hiv
CR20150454A (es) Compuestos amida para el tratamiento de vih
NZ729150A (en) Antiretroviral agents
EA201890735A1 (ru) Модуляторы корового белка вируса гепатита b
CL2017001798A1 (es) Compuestos de pirazina para el tratamiento de enfermedades infecciosas.
EA201691261A1 (ru) Новые дигидрохинолизиноны для лечения и профилактики инфекции, вызванной вирусом гепатита b
EA201691726A1 (ru) Новые 6-конденсированные гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
BR112022000503A2 (pt) Compostos úteis para tratar infecções por vírus influenza
BR112016005270A2 (pt) compostos de aza-piridona, composições farmacêuticas e seus usos
BR112017004524A2 (pt) pirrolopirimidinas para uso na infecção pelo vírus da gripe
BR112018014794A2 (pt) pirimidinas substituídas com arila para uso em infecção pelo vírus influenza
EA201891278A1 (ru) Гетероциклические индолы для применения при инфекции, вызванной вирусом гриппа
CY1118399T1 (el) Ενωσεις βενζοφουρανιου για την θεραπεια μολυνσεων ιου ηπατιτιδας c
BR112017013286A2 (pt) composto de isoxazolina, e, uso de um composto de isoxazolina.
EA201990295A1 (ru) Терапевтические соединения, которые можно применять для профилактического или терапевтического лечения инфекции вирусом вич
BR112018014622A2 (pt) ?composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, métodos para tratar uma infecção por hiv e para prevenir uma infecção por hiv, e, uso de um composto ou sal?
PL409016A1 (pl) N-sulfonowa pochodna polialliloaminy, zastosowanie N-sulfonowej pochodnej polialliloaminy jako leku, zwłaszcza do profilaktyki i leczenia infekcji wirusem grypy typu A (IAV) oraz kompozycja farmaceutyczna zawierająca N-sulfonową pochodną polialliloaminy
EA201691835A1 (ru) Аллостерические модуляторы капсидного белка гепатита в
MX2016009250A (es) Nuevos imidazoles para el tratamiento y profilaxis de la infeccion por virus sincicial respiratorio.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/08/2017, OBSERVADAS AS CONDICOES LEGAIS.

B09W Correction of the decision to grant [chapter 9.1.4 patent gazette]

Free format text: O PRESENTE PEDIDO TEVE UM PARECER DE DEFERIMENTO NOTIFICADO NA RPI NO 2605 DE 08-12-2020, TENDO SIDO CONSTATADO QUE ESTA NOTIFICACAO FOI EFETUADA COM INCORRECOES (ERRO NO NUMERO DE PAGINAS DO RELATORIO DESCRITIVO ? QUADRO 1), ASSIM RETIFICA-SE A REFERIDA PUBLICACAO.